Synthetic Biologics is developing cutting-edge therapeutics to treat pathogen-specific diseases.
Our two leading candidates are:
SYN-004 (ribaxamase) to prevent C. difficile infection and antibiotic-associated diarrhea
SYN-010 to treat irritable bowel syndrome with constipation (IBS-C)
We are a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
ROCKVILLE, Md., March 7, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical